TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

计划入组 9 人 · 首次发布于 2018 年 4 月 20 日

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

计划入组 47 人 · 首次发布于 2017 年 1 月 5 日

Personalized Therapy of Precursor Lymphoid Neoplasms

计划入组 200 人 · 首次发布于 2012 年 8 月 15 日

RETROTRANSPOSON(Myeloid Therapeutics)

MT-303(Myeloid)

Acute myeloid leukaemia(Dania)

MYELOID THERAPEUTICS

United States

Bio-Path Holdings

United States

BioLine Rx

Israel

FDA Approves Pemigatinib for Rare FGFR1-Rearranged Myeloid/Lymphoid Neoplasms Following Stanford-Led Phase II Trial

Germline Variants Define Prognostic Subgroups in Therapy-Related Myeloid Neoplasms

Olverembatinib Shows Promising Results in Multiple Philadelphia Chromosome-Positive ALL Studies